Undervalued biotech equities are frequently identified among small-cap and micro-cap firms that possess approved commercial products or promising Phase 3 clinical pipelines but suffer from depressed valuations due to broader sector sell-offs. Screening these opportunities requires analyzing their cash burn rates, debt levels, and upcoming clinical catalysts.